The Right Care Depends on Your Joint and Your Needs

Exercise can strengthen the muscles around a sore joint

The right exercise can help the muscles support your knee, hip, or shoulder. It shouldn't keep setting off the same soreness.

Small changes at work or on a walk may reduce strain too. Your plan needs to say which tasks to change and for how long.

Medicine or office care may also come up. Ask how soon relief may start and how long it may last.

Surgery can make sense if worn tissue badly limits your day. A fair visit won't make an operation sound like a failure.

Platelet-rich plasma, or PRP, is prepared from your blood

Staff take some blood, then spin it to gather platelets, tiny blood parts used during healing. That prepared blood becomes a shot in the sore area.

The aim is to ease symptoms, but PRP hasn't been shown to rebuild a worn joint. Research on knee soreness is mixed, so relief isn't certain.

Concentrated PRP is one kind of orthobiologics, a group of blood- or tissue-based shots. QC Kinetix medical providers are the health staff who examine you.

They can discuss regenerative treatment choices, meaning blood-based office care. The name doesn't mean your joint grows back.

Ask why your exam makes PRP suitable and what would make it a poor fit. Patients generally pay themselves, so get the cost before deciding.

Timing and cost belong in the choice

A cortisone shot may help sooner, while a PRP shot may take longer. Ask when you may drive, work, walk farther, and return for follow-up.

Get one written total before agreeing to care. Price can matter as much as time away from normal tasks.

Knee or hip surgery alternatives don't mean surgery can always wait. The exam may show that another kind of care needs attention first.

Ask which part of your exam could make PRP a poor fit. If the answer isn't clear, you don't have enough to decide.

Sources

1. The AAOS third-edition clinical practice guideline on non-arthroplasty management of knee osteoarthritis contains 29 recommendations and explicitly highlights intra-articular corticosteroid, hyaluronic acid AND platelet-rich plasma as the areas where better research is still needed - including osteoarthritis characterisation, subgroup and severity stratification, control for bias, and cost-effectiveness analysis.

   Brophy RH, Fillingham YA. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.

2. A network meta-analysis restricted to LARGE randomized trials (at least 100 patients per group; 57 RCTs, 22,795 participants, 18 intra-articular interventions) found treatment effects were consistently larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. In the main analysis excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6; hyaluronic acid had no effect on pain (SMD -0.04, 95% CrI -0.19 to 0.11, 11 trials) but higher odds of dropouts due to adverse events (OR 2.01) and of serious adverse events (OR 1.86). The effects of 16 of the 18 interventions were smaller than the MID and most were consistent with placebo effects.

   Pereira TV, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

3. A network meta-analysis of 79 RCTs (8,761 patients) covering eleven injectables - autologous conditioned serum, BMAC, botulinum toxin, corticosteroid, HA, MSC, ozone, saline placebo, PRP, PRGF and stromal vascular fraction - found the top-ranked treatment CHANGES WITH TIME POINT: high-molecular-weight HA plus corticosteroid ranked first for WOMAC at 4-6 weeks and 3 months, while PRP ranked first at 6 months. This is the clearest demonstration that 'which injection is best' depends entirely on when you measure.

   Anil U, et al. — The efficacy of intra-articular injections in the treatment of knee osteoarthritis: A network meta-analysis of randomized controlled trials.. The Knee, 2021. DOI: 10.1016/j.knee.2021.08.008.

4. A network meta-analysis of 64 trials (9,710 patients) that deliberately separated WITHIN-CLASS variants found high-molecular-weight hyaluronic acid was the only treatment whose confidence interval lay entirely above the minimal important difference for BOTH pain and function. PRP's pain estimate also cleared the MID but varied across sensitivity analyses, leaving its efficacy uncertain; extended-release corticosteroid showed possible benefit over standard-release corticosteroid.

   Phillips M, et al. — Differentiating factors of intra-articular injectables have a meaningful impact on knee osteoarthritis outcomes: a network meta-analysis.. Knee Surgery, Sports Traumatology, Arthroscopy, 2020. DOI: 10.1007/s00167-019-05763-1.

5. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature Medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

6. The 2025 Cochrane review of stem cell injections for knee osteoarthritis pooled 25 randomised trials (1,341 participants) and found that, compared with placebo injection, stem cell injection MAY slightly improve pain (1.2 points better on a 0-10 scale, 7 studies, 445 participants) and function (14.2 points better on a 0-100 scale, 7 studies, 432 participants) up to six months - both rated LOW-certainty evidence, downgraded for indirectness (cell source, preparation and dose varied across studies) and suspected publication bias, since up to three larger RCTs were conducted and withdrawn before reporting results. Radiographic progression was not assessed in any included study.

   Whittle SL, et al. — Stem cell injections for osteoarthritis of the knee.. Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD013342.pub2.

7. RESTORE, the largest and most rigorously blinded placebo-controlled PRP trial in knee OA (n=288, participant-, injector- and assessor-blinded), gave three weekly injections of a commercial leukocyte-poor PRP or saline. At 12 months the change in knee pain was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and the change in medial tibial cartilage volume was -1.4% vs -1.2% (difference -0.2%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no between-group difference. The authors concluded the findings do not support the use of PRP for knee OA.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

8. A meta-analysis of 34 RCTs (1,403 PRP knees vs 1,426 controls) found WOMAC favoured PRP over placebo at 12 months and over hyaluronic acid at 6 and 12 months, and favoured PRP over steroids on VAS pain, KOOS pain, daily function and quality of life at 6 months. Crucially, the authors state that the superiority of PRP DID NOT REACH the minimal clinically important difference for any outcome and the quality of evidence was low.

   Filardo G, et al. — PRP Injections for the Treatment of Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials.. Cartilage, 2021. DOI: 10.1177/1947603520931170.

9. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.